Form D · Pharmaceuticals
Pivot Pharmaceuticals Inc.
Vancouver, A1 · CIK 0001464165
Offering snapshot reported Dec 8, 2015 · SEC filing
- Reported sold
- $4.23M Offering amount: $4.23M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 20, 2015 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Dec 8, 2015 | Initial | $4,227,500 | No comparison | 9 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 05, 06b, 4a5
- Duration over one year
- No
- Business combination
- Yes
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-252581
The securities were issued pursuant to a merger of Pivot Pharmaceuticals, Inc. and IndUS Pharmaceuticals, Inc. in which 4,750,000 shares of Pivot were issued at a price of $0.89 per share.
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| None | None |
Source: Form D, filed Dec 8, 2015. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Pravin Chaturvedi | Director, Executive |
| Ahmad Doroudian | Director |
| Patrick Frankham | Director |
| Moira Ong | Executive |
| Wolfgang Renz | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1275 West 6 Th Avenue Suite 300
Vancouver, A1, V6H 1A6
Vancouver, A1, V6H 1A6